Patents Assigned to Lumosa Therapeutics Co., Ltd.
-
Patent number: 11707501Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.Type: GrantFiled: May 23, 2022Date of Patent: July 25, 2023Assignee: LUMOSA THERAPEUTICS CO., LTDInventor: David Chih-Kuang Chou
-
Patent number: 11338008Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.Type: GrantFiled: September 24, 2020Date of Patent: May 24, 2022Assignee: LUMOSA THERAPEUTICS CO., LTDInventor: David Chih-Kuang Chou
-
Publication number: 20220056149Abstract: The disclosure relates to fusion proteins, methods of making fusion proteins, and methods of using fusion proteins, wherein the fusion proteins comprise a functional single-domain antibody (sdAb) or a functional variant thereof and a cytosine deaminase (CD) protein or a functional variant thereof, optionally connected via a peptide linker. The fusion proteins of the disclosure also have CD activity. The disclosure also relates to pharmaceutical compositions or formulations comprising such fusion proteins and pharmaceutically acceptable excipients, as well as medical uses of these fusion proteins.Type: ApplicationFiled: September 3, 2021Publication date: February 24, 2022Applicants: LUMOSA THERAPEUTICS, CO., LTD., SHANGHAI LUMOSA THERAPEUTICS, CO., LTD.Inventors: Pei-Jiun CHEN, Shu-Hua LEE
-
Patent number: 11241424Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.Type: GrantFiled: December 30, 2019Date of Patent: February 8, 2022Assignees: Lumosa Therapeutics Co., Ltd., Shanghai Lumosa Therapeutics Co., Ltd.Inventors: Chan-Jung Li, David Chih-Kuang Chou, Jin-Ding Huang, Shin-Jr Tsai, Shu-Wen Kuo, Yu-En Tien
-
Patent number: 11234974Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.Type: GrantFiled: November 19, 2018Date of Patent: February 1, 2022Assignees: Lumosa Therapeutics Co., Ltd., Shanghai Lumosa Therapeutics Co., Ltd.Inventors: Chan-Jung Li, David Chih-Kuang Chou, Jin-Ding Huang, Shin-Jr. Tsai, Shu-Wen Kuo, Yu-En Tien
-
Patent number: 10806798Abstract: The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.Type: GrantFiled: May 29, 2018Date of Patent: October 20, 2020Assignee: Shanghai Lumosa Therapeutics Co., Ltd.Inventors: Shiqi Peng, Ming Zhao, Xueyun Jiang
-
Patent number: 10351594Abstract: The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below: wherein the definitions of T, Q, R1 and R2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.Type: GrantFiled: January 3, 2018Date of Patent: July 16, 2019Assignee: Shanghai Lumosa Therapeutics Co., Ltd.Inventors: Shi-Qi Peng, Ming Zhao, Jian-Hui Wu, Yu-Ji Wang, Qi-Qi Feng
-
Publication number: 20190202931Abstract: The disclosure relates to fusion proteins, methods of making fusion proteins, and methods of using fusion proteins, wherein the fusion proteins comprise a functional single-domain antibody (sdAb) or a functional variant thereof and a cytosine deaminase (CD) protein or a functional variant thereof, optionally connected via a peptide linker. The fusion proteins of the disclosure also have CD activity. The disclosure also relates to pharmaceutical compositions or formulations comprising such fusion proteins and pharmaceutically acceptable excipients, as well as medical uses of these fusion proteins.Type: ApplicationFiled: January 4, 2019Publication date: July 4, 2019Applicants: LUMOSA THERAPEUTICS, CO., LTD., SHANGHAI LUMOSA THERAPEUTICS, CO., LTD.Inventors: Pei-Jiun CHEN, Shu-Hua LEE
-
Patent number: 10183018Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.Type: GrantFiled: May 27, 2016Date of Patent: January 22, 2019Assignees: Lumosa Therapeutics Co., Ltd., Shanghai Lumosa Therapeutics Co., Ltd.Inventors: Chan-Jung Li, David Chih-Kuang Chou, Jin-Ding Huang, Shin-Jr. Tsai, Shu-Wen Kuo, Yu-En Tien
-
Patent number: 9890193Abstract: The present invention relates to a compound simultaneously having triple activities of thrombolysis, antithrombosis and free radical scavenging, as well as the preparation method, composition, and applications thereof. The compound is represented by the formula I shown below: wherein the definitions of T, Q, R1 and R2 are described herein. The compound of the present invention simultaneously has triple functions of thrombolysis, free radical scavenging and thrombus-targeting/antithrombosis. The present invention also relates to a pharmaceutical composition comprising the compound, and a preparation method and a nanostructure of the compound.Type: GrantFiled: December 2, 2015Date of Patent: February 13, 2018Assignee: Shanghai Lumosa Therapeutics Co., Ltd.Inventors: Shi-Qi Peng, Ming Zhao, Jian-Hui Wu, Yu-Ji Wang, Qi-Qi Feng